Clinical Trials
11 trialsNCT01107522 2025-09-09
Safety and Tolerability of Carboxyamidotriazole Orotate (CTO) in Solid Tumors or With Temodar® in Glioblastoma or Other Recurrent Malignant Gliomas or in Combination With Temodar® and Radiation Therapy for Patients With Newly Diagnosed Glioblastoma and Malignant Gliomas
Tactical Therapeutics, Inc.
Phase 1 Unknown
NCT05700955 2023-01-26
Neoadjuvant Chemoimmunotherapy in Recurrent Glioblastoma
University of Louisville
Phase 1 Unknown
NCT04385173 2022-12-28
Pilot Study of B7-H3 CAR-T in Treating Patients With Recurrent and Refractory Glioblastoma
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 1 Unknown
NCT03463733 2020-10-08
HUTMZ
Amsterdam UMC, location VUmc
Phase 1 Unknown
NCT03687034 2019-02-26
A Study of the Safety and Pharmacokinetics of BRCX014 in Patients With Glioblastoma
Leaf Vertical Inc.
Phase 1 Unknown
NCT00083096 2015-02-10
Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00516607 2015-02-10
Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas
European Organisation for Research and Treatment of Cancer - EORTC
Phase 1 Unknown
NCT00003747 2013-09-20
Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00016055 2013-09-20
Biological Therapy and Temozolomide in Treating Patients With Metastatic Melanoma
National Cancer Institute (NCI)
Phase 1 Unknown
NCT00409383 2011-11-07
Abraxane and Temodar Plus Genasense in Advanced Melanoma
Genta Incorporated
Phase 1 Unknown
NCT00768911 2010-10-27
CT-322 in Combination With Radiation Therapy and Temozolomide to Treat Newly Diagnosed Glioblastoma Multiforme
Adnexus, A Bristol-Myers Squibb R&D Company
Phase 1 Unknown